AURA Stock Analysis: Aura Biosciences | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 718m USD | 12M Return: 14.1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 4.23M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 4.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Aura Biosciences is a clinical-stage biotechnology company headquartered in Boston, Massachusetts, founded in 2009 and listed on NASDAQ since October 2021. The company develops precision therapies for solid tumors using a proprietary platform that links virus-like particles to drugs or nucleic acids to create virus-like drug conjugates (VDCs).
Its lead asset, bel-sar, is in late-stage clinical development for primary choroidal melanoma and other ocular oncology indications, with early-stage work in bladder cancer. As a clinical-stage biotech, Aura does not yet have approved products or recurring commercial revenue, and its valuation is largely tied to the progression of its R&D pipeline and clinical trial outcomes.
- Bel-sar Phase 3 efficacy data readout in choroidal melanoma
- FDA breakthrough designation accelerates bel-sar regulatory pathway
- Limited cash runway risks dilutive equity offering
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.67 > 0.02 and ΔFCF/TA -15.04 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.66 > 3% & CFO -91.3m > Net Income -112.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.09 > 1.5 & < 3 |
| Outstanding Shares: last quarter (67.4m) vs 12m ago 34.56% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.80%; Δ -0.80% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.74 (Total Current Assets 118.5m - Total Current Liabilities 16.7m) / Total Assets 137.7m |
| B: -3.73 (Retained Earnings -514.1m / Total Assets 137.7m) |
| C: -0.77 (EBIT TTM -112.3m / Avg Total Assets 146.5m) |
| D: 3.52 (Book Value of Equity 107.2m / Total Liabilities 30.4m) |
| Altman-Z'' = -8.77 = D |
As of July 08, 2026, the stock is trading at USD 7.03 with a total of 814,995 shares traded. Over the past week, the price has changed by +2.18%, over one month by +8.49%, over three months by +6.03% and over the past year by +14.12%.
Current recommended Stop Loss: 6.30 (which is 10.4% or 1.4 ATR below the current price).
Aura Biosciences has received a consensus analysts rating of 4.57. Therefore, it is recommended to buy AURA.
- StrongBuy: 4
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 18.8 | 167.4% |
P/B = 7.4457
Revenue TTM = 0.0 USD
EBIT TTM = -112.3m USD
EBITDA TTM = -111.2m USD
Long Term Debt = 13.7m USD (estimated: total debt 17.0m - short term 3.27m)
Short Term Debt = 3.27m USD (from shortTermDebt, last quarter)
Debt = 17.0m USD (from shortLongTermDebtTotal, last quarter) (leases 17.0m already included)
Net Debt = -97.7m USD (calculated: Debt 17.0m - CCE 114.7m)
Enterprise Value = 620.1m USD (717.8m + Debt 17.0m - CCE 114.7m)
Interest Coverage Ratio = unknown (Ebit TTM -112.3m / Interest Expense TTM 0.0)
EV/FCF = -6.77x (Enterprise Value 620.1m / FCF TTM -91.6m)
FCF Yield = -14.78% (FCF TTM -91.6m / Enterprise Value 620.1m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 274k) / Revenue TTM)
Tobins Q-Ratio = 4.50 (Enterprise Value 620.1m / Total Assets 137.7m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 17.0m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -88.7m (EBIT -112.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.09 (Total Current Assets 118.5m / Total Current Liabilities 16.7m)
Debt / Equity = 0.16 (Debt 17.0m / totalStockholderEquity, last quarter 107.2m)
Debt / EBITDA = 0.88 (negative EBITDA) (Net Debt -97.7m / EBITDA -111.2m)
Debt / FCF = 1.07 (negative FCF - burning cash) (Net Debt -97.7m / FCF TTM -91.6m)
Total Stockholder Equity = 143.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -76.70% (Net Income -112.4m / Total Assets 137.7m)
RoE = -78.12% (Net Income TTM -112.4m / Total Stockholder Equity 143.9m)
RoCE = -71.26% (EBIT -112.3m / Capital Employed (Equity 143.9m + L.T.Debt 13.7m))
RoIC = -71.40% (negative operating profit) (NOPAT -88.7m / Invested Capital 124.2m)
WACC = 9.36% (E(717.8m)/V(734.8m) * Re(9.58%) + D(17.0m)/V(734.8m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.58% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.11 | Cagr: 20.38%
[DCF] Fair Price = unknown (Cash Flow -91.6m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.31 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.38 | Chg30d=+7.41% | Revisions=+17% | Analysts=4
EPS next Quarter (2026-09-30): EPS=-0.37 | Chg30d=+6.37% | Revisions=+17% | Analysts=4
EPS current Year (2026-12-31): EPS=-1.59 | Chg30d=+0.47% | Revisions=+17% | GrowthEPS=+9.4% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-1.67 | Chg30d=-2.30% | Revisions=-17% | GrowthEPS=-4.5% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +13% (up=7, down=5)